(NOVO-B) Novo Nordisk - CO
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: CO (Denmark) | Market Cap: 1.292.734m DKK | Total Return: -39.2% in 12m
Avg Turnover: 1.45B
EPS Trend: 93.7%
Qual. Beats: 1
Rev. Trend: 97.0%
Qual. Beats: 1
Warnings
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
Novo Nordisk A/S is a Denmark-based healthcare company specializing in chronic disease treatments, primarily operating through its Obesity and Diabetes Care and Rare Disease segments. The company’s portfolio includes insulin delivery systems, hormone replacement therapies, and GLP-1 receptor agonist treatments for weight management.
The business model relies heavily on a vertically integrated supply chain for biologics, where large-scale manufacturing of proteins and peptides is a significant barrier to entry. As a dominant player in the metabolic health sector, the company captures market share through long-term maintenance therapies rather than one-time curative treatments.
Novo Nordisk maintains a global distribution network covering North America, Europe, and Asia-Pacific. Its product development focuses on transitioning traditional injectable medications to oral formulations and digital health tools, such as smart insulin pens and dose guidance applications, to improve patient adherence.
- GLP-1 sales growth driven by Wegovy and Ozempic demand
- Manufacturing capacity expansion for injectable obesity and diabetes drugs
- Competition intensifies from Eli Lilly and emerging biotech challengers
- Medicare price negotiations and US drug pricing legislation impact margins
| Net Income: 122b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -9.73 > 1.0 |
| NWC/Revenue: -14.59% < 20% (prev -20.36%; Δ 5.77% < -1%) |
| CFO/TA 0.21 > 3% & CFO 119b > Net Income 122b |
| Net Debt (133b) to EBITDA (178b): 0.75 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.45b) vs 12m ago 0.05% < -2% |
| Gross Margin: 81.85% > 18% (prev 84.33%; Δ -2.48% > 0.5%) |
| Asset Turnover: 62.53% > 50% (prev 61.97%; Δ 0.56% > 0%) |
| Interest Coverage Ratio: 7.36 > 6 (EBIT TTM 161b / Interest Expense TTM 21.8b) |
| A: -0.09 (Total Current Assets 177b - Total Current Liabilities 225b) / Total Assets 559b |
| B: 0.37 (Retained Earnings 206b / Total Assets 559b) |
| C: 0.31 (EBIT TTM 161b / Avg Total Assets 524b) |
| D: 0.57 (Book Value of Equity 203b / Total Liabilities 356b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 1.07 (Receivables 100b/86.4b, Revenue 328b/303b) |
| GMI: 1.03 (GM 84.33% / 81.85%) |
| AQI: 0.99 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 1.08 (Revenue 328b / 303b) |
| TATA: 0.01 (NI 122b - CFO 119b) / TA 559b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at DKK 280.10 with a total of 4,022,134 shares traded.
Over the past week, the price has changed by -0.87%,
over one month by -2.06%,
over three months by +19.98% and
over the past year by -39.24%.
Novo Nordisk has no consensus analysts rating.
P/E Trailing = 10.6512
P/E Forward = 12.7226
P/S = 3.9437
P/B = 6.1121
P/EG = 3.1588
Revenue TTM = 328b DKK
EBIT TTM = 161b DKK
EBITDA TTM = 178b DKK
Long Term Debt = 119b DKK (from longTermDebt, last quarter)
Short Term Debt = 27.2b DKK (from shortTermDebt, last quarter)
Debt = 155b DKK (from shortLongTermDebtTotal, last quarter) + Leases 8.57b
Net Debt = 133b DKK (calculated: Debt 155b - CCE 21.6b)
Enterprise Value = 1426b DKK (1293b + Debt 155b - CCE 21.6b)
Interest Coverage Ratio = 7.36 (Ebit TTM 161b / Interest Expense TTM 21.8b)
EV/FCF = 45.96x (Enterprise Value 1426b / FCF TTM 31.0b)
FCF Yield = 2.18% (FCF TTM 31.0b / Enterprise Value 1426b)
FCF Margin = 9.47% (FCF TTM 31.0b / Revenue TTM 328b)
Net Margin = 37.20% (Net Income TTM 122b / Revenue TTM 328b)
Gross Margin = 81.85% ((Revenue TTM 328b - Cost of Revenue TTM 59.5b) / Revenue TTM)
Gross Margin QoQ = 85.96% (prev 80.86%)
Tobins Q-Ratio = 2.55 (Enterprise Value 1426b / Total Assets 559b)
Interest Expense / Debt = 14.09% (Interest Expense 21.8b / Debt 155b)
Taxrate = 21.66% (33.7b / 156b)
NOPAT = 126b (EBIT 161b * (1 - 21.66%))
Current Ratio = 0.79 (Total Current Assets 177b / Total Current Liabilities 225b)
Debt / Equity = 0.76 (Debt 155b / totalStockholderEquity, last quarter 203b)
Debt / EBITDA = 0.75 (Net Debt 133b / EBITDA 178b)
Debt / FCF = 4.30 (Net Debt 133b / FCF TTM 31.0b)
Total Stockholder Equity = 184b (last 4 quarters mean from totalStockholderEquity)
RoA = 23.27% (Net Income 122b / Total Assets 559b)
RoE = 66.36% (Net Income TTM 122b / Total Stockholder Equity 184b)
RoCE = 53.07% (EBIT 161b / Capital Employed (Equity 184b + L.T.Debt 119b))
RoIC = 36.52% (NOPAT 126b / Invested Capital 345b)
WACC = 9.52% (E(1293b)/V(1448b) * Re(9.34%) + D(155b)/V(1448b) * Rd(14.09%) * (1-Tc(0.22)))
Discount Rate = 9.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -0.10%
[DCF] Terminal Value 68.84% ; FCFF base≈48.5b ; Y1≈42.5b ; Y5≈34.4b
[DCF] Fair Price = 98.19 (EV 463b - Net Debt 133b = Equity 329b / Shares 3.35b; r=9.52% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 93.75 | EPS CAGR: 19.66% | SUE: 4.0 | # QB: 1
Revenue Correlation: 97.01 | Revenue CAGR: 19.23% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=5.17 | Chg30d=-2.48% | Revisions=+14% | Analysts=5
EPS next Quarter (2026-09-30): EPS=5.00 | Chg30d=-2.88% | Revisions=+14% | Analysts=5
EPS current Year (2026-12-31): EPS=21.00 | Chg30d=+0.48% | Revisions=+67% | GrowthEPS=-8.8% | GrowthRev=-5.3%
EPS next Year (2027-12-31): EPS=21.46 | Chg30d=+0.43% | Revisions=+40% | GrowthEPS=+2.2% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: +67%